Comparison of Values for Screening Programs

Draft - based on 4/29/02 models

Type of Disorder		Rankings Basis			DOH Lab Test Without Tandem Mass Spectrometry									
	Frequency in 1 per listed basis	Cost	Net Benefit	Cos	st of Screen	N	let Benefits		Net w/o Mortality	\$	/ year of life	All normal life		
Homocystinuria	361,336	1		\$	2,900,000	\$	(1,700,000)	\$	(2,000,000)	\$	600,000	-		
MSUD	130,745	1	7	\$	2,900,000	\$	3,800,000	\$	(2,200,000)	\$	30,000	-		
Biotinidase	80,423	2	5	\$	3,300,000	\$	9,300,000	\$	(2,200,000)	\$	40,000	+		
Galactosemia	60,002	1	3	\$	2,900,000	\$	14,100,000	\$	(4,000,000)	\$	30,000	-		

Type of Disorder		Rankings	Basis	DOH Lab Test With Tandem Mass Spectrometry									
	Frequency in 1 per listed basis	Cost	Net Benefit	Co	st of Screen	Net Benefits			Net w/o Mortality		/ year of	All normal life	
MCAD*	23,000	3	4	\$	12,700,000	\$	13,300,000	\$	90,000	\$	90,000	+	
Homocystinuria	180,668		8	\$	1,100,000	\$	1,500,000			\$	120,000	-	
MSUD	130,745		6	\$	1,100,000	\$	5,600,000	\$	(400,000)	\$	10,000	-	
Tandam Masa Cras		1	2	ф.	14 000 000	ው	20 400 000	Φ.	700 000	ው	70.000		
Tandem Mass Spec		4	2	\$	14,900,000	\$	20,400,000	\$	700,000	\$	70,000		